PREF-NET: A patient preference and experience study of lanreotide autogel (LAN) administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the UK

#3727

Introduction: The somatostatin analogue LAN is a common first-line treatment for NETs that can be given at home in a ready-to-use syringe every 4 weeks in the UK.

Aim(s): To generate real-world evidence of experiences with LAN at home and in hospital, and the impact of treatment setting on patients’ lives.

Materials and methods: PREF-NET was a multicentre, cross-sectional, patient-reported, 2-part study of UK adults with GEP-NETs, comprising: i) a quantitative online survey, ii) qualitative semi-structured interviews with a subgroup of respondents. Eligible patients were aged ≥18 years with GEP-NETs and on a stable LAN dose given at home, having switched from hospital administration 4–24 months prior. The primary endpoint was overall preference for LAN administration at home vs the hospital setting, assessed using mixed methods analysis.

Conference:

Presenting Author: Khan M

Authors: Khan M, Davies L, Back M, Shah T, Pritchard D,

Keywords: patient participation, somatostatin analogues, injections, quality of life, value-based health care,